ClinicalTrials.gg

Program

Immunoglobulin G

Also written as “HYQVIA”, “HyQvia” and “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”.

Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Prostatic Neoplasms · Autoimmune Diseases of the Nervous System · Alzheimer Disease, led by 6 companies.

Furthest: phase 4, since Apr 12, 201713 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda60 open or runningphase 4since Apr 12, 2017Sep 11, 2015none ahead
GC Biopharma30 open or runningphase 4since Jan 25, 2012Mar 14, 2011none ahead
CSL10 open or runningphase 3since May 16, 2008May 16, 2008none ahead
Genmab10 open or runningphase 2since May 14, 2020May 14, 2020none ahead
Hoffmann-La Roche10 open or runningphase 1since May 30, 2025May 30, 2025none ahead
Proclara Biosciences10 open or runningphase 1since Dec 23, 2016Dec 23, 2016none ahead

Also a collaborator on its studies: takeda-development-center-americas-inc, baxalta-innovations-gmbh-now-part-of-shire, AbbVie and symyoo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2008First study: phase 3 study in Primary Immunodeficiency DiseasesNew to CSLCSL · NCT00680446 · 41 enrolled · Australia, New Zealand
  2. Mar 14, 2011GC Biopharma's first study: phase 3 study in SepsisNew to GC BiopharmaGC Biopharma · NCT01315496 · 214 enrolled · Korea, Republic of
  3. Jan 25, 2012Phase 4 study in Mucocutaneous Lymph Node SyndromeGC Biopharma · NCT01524939 · 45 enrolled · Korea, Republic of
  4. Sep 11, 2015Takeda's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
  5. Nov 2, 2016Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT02955355 · 85 enrolled · United States, Argentina, Brazil and more
  6. Dec 23, 2016Proclara Biosciences's first study: phase 1 study in Alzheimer DiseaseNew to Proclara BiosciencesProclara Biosciences · NCT03008161 · 83 enrolled · United States
  7. Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesTakeda · NCT03116347 · 42 enrolled · Czechia, Denmark, France and more
  8. Sep 7, 2017Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT03277313 · 44 enrolled · United States
  9. Nov 21, 2019Phase 2 study in Autoimmune Diseases of the Nervous SystemGC Biopharma · NCT04175522 · 23 enrolled · Korea, Republic of
  10. May 14, 2020Genmab's first study: phase 2 study in Prostatic NeoplasmsNew to GenmabGenmab · NCT04424641 · 48 enrolled · United States, Denmark, Israel and more
  11. Jul 7, 2020Phase 1 study in Healthy VolunteersTakeda · NCT04578535 · 51 enrolled · United States
  12. Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
  13. May 30, 2025Hoffmann-La Roche's first study: phase 1 study in Healthy ParticipantsNew to Hoffmann-La RocheHoffmann-La Roche · NCT07025577 · 82 enrolled · United States
  14. Oct 19, 2026Primary completion moved from 2028-02-28 to 2029-05-06Date moved laterphase 2 · +14 months · NCT07048262

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07025577Healthy Participants · United States1CompletedHoffmann-La RocheAug 8, 202582
NCT06895967Healthy Volunteers · United States1CompletedTakedaJul 24, 202530
NCT04578535Healthy Volunteers · United States1CompletedTakedaMar 2, 202251
NCT04424641Prostatic Neoplasms · United States, Denmark, Israel and more2TerminatedGenmabOct 29, 202148
NCT04175522Autoimmune Diseases of the Nervous System · Korea, Republic of2CompletedGC BiopharmaJun 11, 202023
NCT03277313Primary Immunodeficiency Diseases · United States3CompletedTakedaJul 20, 202244
NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more4CompletedTakedaJan 15, 202142
NCT03008161Alzheimer Disease · United States1CompletedProclara BiosciencesFeb 6, 201983
NCT02955355Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedTakedaJul 4, 202385
NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more3CompletedTakedaFeb 23, 2022138
NCT01524939Mucocutaneous Lymph Node Syndrome · Korea, Republic of4CompletedGC BiopharmaSep 201245
NCT01315496Sepsis · Korea, Republic of3TerminatedGC BiopharmaDec 2013214
NCT00680446Primary Immunodeficiency Diseases · Australia, New Zealand3CompletedCSLMay 201341

How it is read

Names in the registry

  • “HYQVIA”, 10 entries
  • “Immunoglobulin G”, 3 entries
  • “HyQvia”, 1 entry
  • “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”, 1 entry
  • “NPT088”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.